Paper34523908
Prioritization of Molecular Targets for Antimalarial Drug Discovery.
Forte B and 20 others. ACS Infect Dis, 2021. Cited by 69 papers, by iCite.
Cite this record
ConductScience Library. Prioritization of Molecular Targets for Antimalarial Drug Discovery. Papers, record 34523908. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34523908
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antimalarials | Major topic |
| Malaria | Major topic |
| Plasmodium | Major topic |
| Drug Discovery | |
| Humans |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Wellcome Trust | United Kingdom | PubMed | PubMed | ||
| R01 AI152533 | NIAID NIH HHS | United States | R01AI152533 | PubMed | NIH RePORTER |
| 203134/Z/16/Z | Wellcome Trust | United Kingdom | PubMed | PubMed |
References58
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33046056 | High prevalence of asymptomatic malaria infections in adults, Ashanti Region, Ghana, 2018. | Malar J | 2020 | https://conductscience.org/library/papers/33046056 | PubMed |
| 2 | 23742293 | Designing the next generation of medicines for malaria control and eradication. | Malar J | 2013 | https://conductscience.org/library/papers/23742293 | PubMed |
| 3 | 17962072 | Target assessment for antiparasitic drug discovery. | Trends Parasitol | 2007 | https://conductscience.org/library/papers/17962072 | PubMed |
| 4 | 32682267 | The antimalarial resistome - finding new drug targets and their modes of action. | Curr Opin Microbiol | 2020 | https://conductscience.org/library/papers/32682267 | PubMed |
| 5 | 20485427 | Thousands of chemical starting points for antimalarial lead identification. | Nature | 2010 | https://conductscience.org/library/papers/20485427 | PubMed |
| 6 | 19068099 | Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. | Cell Microbiol | 2009 | https://conductscience.org/library/papers/19068099 | PubMed |
| 7 | 21401506 | Target validation: linking target and chemical properties to desired product profile. | Curr Top Med Chem | 2011 | https://conductscience.org/library/papers/21401506 | PubMed |
| 8 | 22704625 | Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. | Cell Host Microbe | 2012 | https://conductscience.org/library/papers/22704625 | PubMed |
| 9 | 32109369 | Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle. | Cell Host Microbe | 2020 | https://conductscience.org/library/papers/32109369 | PubMed |
| 10 | 10477522 | Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. | Science | 1999 | https://conductscience.org/library/papers/10477522 | PubMed |
| 11 | 33431920 | An integrated platform for genome engineering and gene expression perturbation in Plasmodium falciparum. | Sci Rep | 2021 | https://conductscience.org/library/papers/33431920 | PubMed |
| 12 | 32084498 | Structure-based view of the druggable genome. | Drug Discov Today | 2020 | https://conductscience.org/library/papers/32084498 | PubMed |
| 13 | 31978322 | The Antimalarial Natural Product Salinipostin A Identifies Essential α/β Serine Hydrolases Involved in Lipid Metabolism in P. falciparum Parasites. | Cell Chem Biol | 2020 | https://conductscience.org/library/papers/31978322 | PubMed |
| 14 | 34348113 | Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. | Cell Chem Biol | 2022 | https://conductscience.org/library/papers/34348113 | PubMed |
| 15 | 29320160 | Efforts Aimed To Reduce Attrition in Antimalarial Drug Discovery: A Systematic Evaluation of the Current Antimalarial Targets Portfolio. | ACS Infect Dis | 2018 | https://conductscience.org/library/papers/29320160 | PubMed |
| 16 | 34001441 | Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials. | Trends Parasitol | 2021 | https://conductscience.org/library/papers/34001441 | PubMed |
| 17 | 33648890 | MalDA, Accelerating Malaria Drug Discovery. | Trends Parasitol | 2021 | https://conductscience.org/library/papers/33648890 | PubMed |
| 18 | 28289248 | Antimalarial Drug Resistance: A Threat to Malaria Elimination. | Cold Spring Harb Perspect Med | 2017 | https://conductscience.org/library/papers/28289248 | PubMed |
| 19 | 24509527 | Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures. | Nat Med | 2014 | https://conductscience.org/library/papers/24509527 | PubMed |
| 20 | 26085270 | A novel multiple-stage antimalarial agent that inhibits protein synthesis. | Nature | 2015 | https://conductscience.org/library/papers/26085270 | PubMed |
Cited by48
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42757160 | Identification, Structure-Activity Relationship (SAR), and Biological Evaluation of New Chemical Series as Malaria Parasite PfGCN5 Bromodomain Inhibitors. | ACS Omega | 2026 | https://conductscience.org/library/papers/42757160 | PubMed |
| 42680902 | New thinking for the next generation of antimalarials. | EMBO Mol Med | 2026 | https://conductscience.org/library/papers/42680902 | PubMed |
| 42653783 | Revisiting Glutathione Transferases of Plasmodium as Potential Targets for Coadjuvant Therapies and the Development of New Antimalarials. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42653783 | PubMed |
| 42315125 | Minimum Inoculum of Resistance Assay for Evaluating Antitoxoplasmosis Compounds That Target Phenylalanine tRNA Synthetase. | ACS Infect Dis | 2026 | https://conductscience.org/library/papers/42315125 | PubMed |
| 42045167 | Identification of an Orally Efficacious Imidazo[4,5-c]pyridine-6-Carboxamide Antimalarial with a High Barrier to Resistance. | J Med Chem | 2026 | https://conductscience.org/library/papers/42045167 | PubMed |
| 42001110 | Targeting protein-protein interactions in Plasmodium: from asexual replication to sexual development. | Parasit Vectors | 2026 | https://conductscience.org/library/papers/42001110 | PubMed |
| 41898232 | Novel Antiplasmodial Natural Products Identified Through a Modified Bioluminescence-Based Rate-of-Kill Assay. | Biomedicines | 2026 | https://conductscience.org/library/papers/41898232 | PubMed |
| 41846953 | Minimum inoculum of resistance assay for evaluating for anti-toxoplasmosis compounds that target phenyl alanine tRNA synthetase. | bioRxiv | 2026 | https://conductscience.org/library/papers/41846953 | PubMed |
| 41693340 | Small Molecule Kinase Inhibitors with In Vitro β-Hematin Formation and Plasmodium falciparum Protein Kinase G Inhibitory Activity Identified Using Machine Learning. | ChemMedChem | 2026 | https://conductscience.org/library/papers/41693340 | PubMed |
| 41025349 | A drug repurposing approach reveals targetable epigenetic pathways in Plasmodium vivax hypnozoites. | Elife | 2025 | https://conductscience.org/library/papers/41025349 | PubMed |
| 40907219 | Investigation of a cryptic ligand binding site on Plasmodium falciparum Hsp90. | Bioorg Med Chem | 2025 | https://conductscience.org/library/papers/40907219 | PubMed |
| 40901734 | Cryptosporidium aspartyl protease 2 is required for host cell egress of merozoites and male gametes. | Mol Biol Cell | 2025 | https://conductscience.org/library/papers/40901734 | PubMed |
| 40628257 | Plasmodiumfalciparum protein kinase 6 and hemozoin formation are inhibited by a type II human kinase inhibitor exhibiting antimalarial activity. | Cell Chem Biol | 2025 | https://conductscience.org/library/papers/40628257 | PubMed |
| 40035447 | Structure-activity analysis of imino-pyrimidinone-fused pyrrolidines aids the development of dual plasmepsin V and plasmepsin X inhibitors. | FEBS J | 2025 | https://conductscience.org/library/papers/40035447 | PubMed |
| 39913579 | The essential genome of Plasmodium knowlesi reveals determinants of antimalarial susceptibility. | Science | 2025 | https://conductscience.org/library/papers/39913579 | PubMed |
| 39848983 | YAT2150 is irresistible in Plasmodium falciparum and active against Plasmodium vivax and Leishmania clinical isolates. | Sci Rep | 2025 | https://conductscience.org/library/papers/39848983 | PubMed |
| 39548094 | Eliminating malaria transmission requires targeting immature and mature gametocytes through lipoidal uptake of antimalarials. | Nat Commun | 2024 | https://conductscience.org/library/papers/39548094 | PubMed |
| 39471233 | A novel 4-aminoquinoline chemotype with multistage antimalarial activity and lack of cross-resistance with PfCRT and PfMDR1 mutants. | PLoS Pathog | 2024 | https://conductscience.org/library/papers/39471233 | PubMed |
| 39466084 | β-Carboline-3-carboxamide Antimalarials: Structure-Activity Relationship, ADME-Tox Studies, and Resistance Profiling. | ACS Infect Dis | 2024 | https://conductscience.org/library/papers/39466084 | PubMed |
| 39345873 | Employing Hexahydroquinolines as PfCDPK4 Inhibitors to Combat Malaria Transmission: An Advanced Computational Approach. | Adv Appl Bioinform Chem | 2024 | https://conductscience.org/library/papers/39345873 | PubMed |
Genes19
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34523908
GET https://conductscience.org/api/papers/v1/34523908/authors?page=2